Moderna, Inc. (NASDAQ:MRNA) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 7.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,585,966 shares of the company's stock after selling 304,846 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.93% of Moderna worth $149,104,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Voloridge Investment Management LLC raised its position in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after buying an additional 1,996,003 shares during the period. Woodline Partners LP raised its position in shares of Moderna by 8.3% during the 4th quarter. Woodline Partners LP now owns 142,523 shares of the company's stock valued at $5,926,000 after buying an additional 10,968 shares during the period. Two Sigma Investments LP raised its position in shares of Moderna by 5.8% during the 4th quarter. Two Sigma Investments LP now owns 664,040 shares of the company's stock valued at $27,611,000 after buying an additional 36,558 shares during the period. Theleme Partners LLP raised its position in shares of Moderna by 1.0% during the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after buying an additional 72,028 shares during the period. Finally, Tang Capital Management LLC acquired a new position in shares of Moderna in the 4th quarter valued at $12,474,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Bank of America decreased their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. UBS Group decreased their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. JPMorgan Chase & Co. decreased their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research note on Thursday, May 22nd. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and decreased their price target for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Finally, Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and an average price target of $53.58.

Moderna Price Performance

Shares of MRNA stock traded up $0.50 during trading hours on Tuesday, reaching $26.76. 14,584,904 shares of the company's stock were exchanged, compared to its average volume of 8,035,397. The company's 50 day moving average is $26.83 and its two-hundred day moving average is $34.20. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $164.73. The company has a market cap of $10.35 billion, a P/E ratio of -2.88 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same quarter in the prior year, the company posted ($3.07) earnings per share. Moderna's quarterly revenue was down 35.3% on a year-over-year basis. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.